Larry Tye, an author and former Boston Globe health reporter, is coauthor, with Kitty Dukakis, of “Shock: The Healing Power ...

The Ensuring Pathways to Innovative Cures Act would extend the time Medicare can negotiate and set prices for small molecule ...

Almost half of patients diagnosed with depression classify as being 'treatment-resistant' as new research suggests that many don't respond to multiple antidepressant options.

Almost half of patients diagnosed with depression classify as being 'treatment-resistant' as new research suggests that many don't respond to multiple antidepressant options.

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Over 30 million Americans take antidepressants. Researchers found four specific types with ties to cognition loss later in ...

New Delhi: India’s drug price regulator has capped the retail prices of 53 formulations or combinations of drugs used in treating pain, depression, diabetes, heart failure, and auto-immune diseases.

Johnson & Johnson is terminating some research for an experimental drug that the company previously predicted could be a multibillion-dollar product. In a statement released Thursday afternoon ...

Brian Abrahams, an analyst at RBC Capital Markets, suspects the discontinued J&J trials could erode “any residual hope” these drugs might be useful in depression. It may also “cast further doubt” on ...

Neumora halted one trial of its depression drug navacaprant and paused a pair of late-stage studies as it tries to learn from a recent phase 3 failure. The KOASTAL-1 study, which read out in ...

Are antidepressants addictive? The short answer is no, say experts who spoke with CNN. There are differences between addiction to (addictive) drugs and a dependency on medications that treat ...